Genetic and Epigenetic Markers to Identify High Risk Patients for Multiple Early Gastric Cancers after Treatment with Endoscopic Mucosal Resection by Fukuda, Mayumi et al.
203
Original Article J. Clin. Biochem. Nutr., 40, 203–209, May 2007
Genetic and Epigenetic Markers to Identify High Risk Patients for 
Multiple Early Gastric Cancers after Treatment with Endoscopic 
Mucosal Resection
Mayumi Fukuda1,2, Hiroshi Yokozaki2, Masatsugu Shiba1, Kazuhide Higuchi1,*, 
and Tetsuo Arakawa1
1Department of Gastroenterology, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, 
Abeno-ku, Osaka 545-8585, Japan
2Division of Surgical Pathology, Department of Biomedical Informatics, Kobe University Graduate School of 
Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan
Received 19 October, 2006; Accepted 25 October, 2006
Summary The development of multiple gastric cancer is a major problem after the endo-
scopic resection of the first early gastric cancer. To find out markers to identify high risk
patients, we analyzed the microsatellite instability (MSI) status and hypermethylation of
tumor-related genes in multiple gastric cancers. Sixty-four adenocarcinomas resected by
endoscopy, including 32 early solitary gastric cancers (SGCs) from 32 patients and 32 multiple
gastric cancers (MGCs) from 14 patients, were employed. We analyzed MSI and the
methylation status of promoter regions of the hMLH1,  MGMT,  p16 and E-cadherin using
methylation-specific Polymerase Chain Reaction. Expression levels of hMLH1 were examined
by immunohistochemistry. MSI (+) was detected in 5 of the 14 (35.7%) patients with MGCs,
and in only 3 of the 32 patients (9.3%) with SGCs. Significant differences were observed
between the 2 groups (p<0.001). Hypermethylation of hMLH1 was more frequently detected
in MGCs than in SGCs (p<0.01), whereas significant difference was not observed in the
frequency of MGMT,  p16 or E-cadherin promoter methylation between the 2 groups. In
conclusion, our results indicate that inactivation of hMLH1 through promoter hyper-
methylation may be involved in the development of multiple gastric cancers following the MSI
pathway.
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Introduction
Due to advances in endoscopic therapeutic techniques
such as mucosal resection, gastric cancers have usually been
treated at an early stage. If it is completely resected by
histology, gastric cancer does not recur at the treated scar.
Different from surgery, almost all gastric mucosa remains
with malignant potential. Multiple gastric cancers are observed
in approximately 3.7–5.7% of all patients with gastric cancer
[1, 2]. Uemura et al. [3] reported that the rates of meta-
chronous multiple gastric cancer were 9% during three years
after the resection of the first gastric cancer. Endoscopists
should carefully follow the patients treated with endoscopic
resection for gastric cancers in order to find metachronous
multiple gastric cancers. It is clinically and economically
important to narrow the number of patients followed by the
high risk factors. However, it is not well-known what these
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risk factors are or the predictive factors for the development
of metachronous multiple gastric cancers.
Microsatellite instability (MSI) due to defects in mismatch
repair genes such as hMLH1 and hMSH2 is now widely
recognized as an important mechanism in tumorigenesis [4–
6]. In addition, epigenetic silencing of tumor suppressor or
tumor-related genes and mismatch repair genes, due to
hypermethylation of cytosine guanine dinucleotides (CpG)
sites in the 5’ promoter resions, has emerged recently as one
of the pivotal genetic alterations in cancer development [7,
8]. Several reports have been published about methylation
of various genes, including hMLH1, O6-methylguanine
DNA methylyransferase (MGMT), E-cadherin and p16, in
chronic gastritis, intestinal metaplasia and adenomas to
carcinomas of the stomach [9–13]. However, few reports
have described about the correlation between the presence of
MSI and DNA hypermethylation in multiple gastric cancers
[14–16]. In order to find genetic and epigenetic markers to
identify high risk patients for multiple early gastric cancers
after treatment with endoscopic mucosal resection (EMR),
we analyzed the MSI status and hypermethylation of
multiple tumor-related genes in these patients comparing




Sixty-four adenocarcinomas, including 32 solitary tumors
from 32 patients and 32 multiple tumors from 14 patients
treated with endoscopic mucosal resection at the Osaka
City University Hospital between 1993 and 2002 were
studied. Written informed concent was obtained from all
patients. These patients received follow-up esophago-
gastro-duodenoscopy at 1 month, 3 months and then every 6
months after the first cancer treatment. The mean age of the
patients with a single gastric cancer and with synchronous
and metachronous multiple gastric cancers was 67.1 and 71.5
years, respectively. The male to female ratios of these groups
were 21/11 and 12/2, respectively. Active Helicobacter
pylori ( H. pylori) infection was identified by histology,
serology test for H. pylori antibody and urea breath test.
Active  H. pylori infection was detected in 14 patients
(43.8%) and in 8 patients (57.1%), respectively.
DNA extraction
Tissue sections, 4 µm in thickness, were cut from formalin-
fixed and paraffin-embedded blocks were placed on a glass
slide and stained with hematoxylin and eosin. These tissue
sections were then dehydrated in graded ethanol solutions
and dried. Cancerous and normal tissues on the slide were
carefully dissected using tooth picks, separately, using the
serial haematoxylin-eosin stained sections under the micro-
scope as a reference. DNA was extracted from the tissues
with 50 µl of extraction buffer (100 mM Tris-HCl, pH 7.8,
2 mM EDTA, 400 µg/ml of proteinase K) at 55°C overnight.
The tubes were boiled for 7 min to inactivate the proteinase
K, and then 1 µl of these extracts were used for each
polymerase chain reaction (PCR) amplification.
Microsatellite assay
Six microsatellite markers (BAT-25, BAT-26, D5S346,
D17S250, D1S191 and BAT40) were analyzed. The forward
primers were fluorescein labeled with [6-FAM] (D1S191,
D17S250, BAT-26 and BAT-40), [VIC] (D5S346) and
[TAMRA] (BAT-25). PCR was performed in total 15 µl
reaction volumes containing 1 µl template DNA, 0.56 µmol/l
of each primer, 74.7 µmol/l of dATP, dGTP, dCTP and dTTP,
respectively, 4.5 mmol/l of MgCl2 and 0.075 U of AmpliTaq
Gold (Applied Biosystems, Foster City, CA). The PCR
amplification consisted of 45 cycles (94°C for 45 s, 55°C for
45 s and 72°C for 45 s) after the initial Taq DNA polymerase
activation step (95°C for 10 min), followed by a final extension
for 10 min at 72°C. PCR products were electrophoresed in
ABI PRISM 310 Genetic Analyzer along with GeneScan-500
[ROX] molecular weight standard (Applied Biosystems).
The size of the PCR product was analyzed using GeneScan
software (Applied Biosystems). Tumors were characterized
as MSI (+) (= MSI-high) if two or more of the markers
showed instability. When one or none of the markers showed
instability, tumors were designated as MSI (−) (= MSS/MSI-
low). We considered MSS (microsatellite stable) and MSI-low
cases together as MSI (−) because there was no statistical
difference between them [17].
Immunohistochemistry
Immunohistochemistry was performed on formalin-fixed,
paraffin-embedded sections using a streptavidin-biotin system
(Dakocytomation, Copenhagen, Denmark). Mouse mono-
clonal antibody to hMLH1 (diluted 1:100), (Pharmingen,
San Diego, CA) was used after antigen retrieval by micro-
wave. Slides were counterstained with Meyer’s haematoxylin.
The evaluation of hMLH1 immunoreativity was categorized
as positive or negative. Cases with definite nuclear staining
in more than 30% of the tumor cells were categorized as
positive and those with definite nuclear staining less than
30% of the tumor cells as negative.
Bisulfite modification and methylation-specific PCR (MSP)
The methylation status of the CpG island in the promoter
region of hMLH1, MGMT, p16 and E-cadherin was determined
by bisulfite treatment of DNA followed by methylation-
specific PCR with some modifications [18]. In brief, 2 µg
of microdissected genomic DNA was denatured by treat-
ment with NaOH and modified with 3 M sodium bisulfite
for 16 h. DNA samples were purified with Wizard DNAEpigenetic Markers for Multiple Early Gastric Cancers
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purification resin (Promega, Madison, WI), treated with
NaOH, precipitated with ethanol, and resuspended in
20 µl of distilled water. The primer sequences of each gene
and conditions of the PCRs were in accordance with those of
the previous reports [18–20]. Ten µl of PCR products
underwent electrophoresis on 8% non-denaturing poly-
acrylamide gels, then visualized under UV illumination
using an ethidium bromide stain. DNA from Colo320 colon
cancer cell line treated with CpG methyltransferase (New
England Biolabs, Beverly, MA) was used as a positive
control for methylation and distilled water was used as a
negative control.
Statistical analysis
Data were analyzed using the SPSS software (SPSS Inc.,
Chicago, IL). Fisher’s exact test were used for analysis of
most of the categorical or numerical data, respectively. In
addition, the cumulative rate of secondary gastric cancer
development in patients with MSI (+) gastric cancer and that
in patients with MSI (−) gastric cancer were calculated by
the Kaplan-Meier method. A p value less than 0.05 was
regarded as statistically significant.
Results
The frequency of MSI
Representative results of microsatellite analyses are shown
in Fig. 1. MSI (+) was detected in 5 of the 14 (35.7%)
patients with multiple gastric cancers (MGCs). On the other
hand, MSI (+) was only detected in 3 of the 32 (9.3%)
patients with solitary gastric cancers (SGC) (Table 1). The
frequency of MSI (+) was significantly higher in the patients
with multiple gastric cancers than that in those with a single
gastric cancer (p<0.001).
There was no statistical difference between SGC and
MGC in evaluated clinicopathologic features including age,
sex, tumor histology, tumor location or H. pylori infection
(Table 2).
Promoter hypermethylation of hMLH1, MGMT, p16 and E-
cadherin
Representative results of MSP of hMLH1, MGMT, p16
Fig. 1.  Representative results of microsatellite analyses in early gastric carcinomas. In case 2 (upper panel), each microsatellite
demonstrates identical pattern between normal gastric mucosa (N) and cancer (T). On the other hand, BAT-26, BAT-25 and BAT
40 show extra-peaks (arrows) in cancer DNA from case 16.
Table 1. Comparison of the frequency of microsatellite instability in early multiple gastric cancers
and early solitary gastric cancers
total MSI (+)a (%) MSI (−)b (%) p value
Patients with solitary gastric cancers 32 3 (9.3%) 29 (90.7%) <0.001
Patients with multiple gastric cancers 14 5 (35.7%) 9 (64.3%)
Solitary gastric lesions 32 3 (9.3%) 29 (90.7%) 0.02
Multiple gastric lesions 32 7 (21.9%) 25 (78.1%)
a MSI (+); two or more of the markers showed instability
b MSI (−); one or none of the markers showed instabilityM. Fukuda et al.
J. Clin. Biochem. Nutr.
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and E-cadherin are shown in Fig. 2. Table 3 summarizes
the frequency of the promoter hypermethylation of each
gene in early SGCs and MGCs. Hypermethylation of hMLH1
was more frequently observed in MGCs than in SGCs
(p<0.01), whereas significant difference was not observed in
the frequency of MGMT,  p16 and E-cadherin promoter
methylation between the 2 groups.
Relationship between promoter hypermethylation and MSI
Next, we compared the frequency of hMLH1, MGMT, p16
and  E-cadherin promoter methylation and microsatellite
status in the early gastric cancers (Fig. 3). Methylation of
hMLH1 was present in 70% (7/10) of MSI (+) tumors and in
14.8% (8/54) of MSI (−) tumors (p<0.01). Methylation of
MGMT was detected in 70% (7/10) of MSI (+) tumors and
in 33.3% (18/54) of MSI (−) tumors (p<0.01). Methylation
of E-cadherin was present in 30% (3/10) of MSI (+) tumors
and in 18.5% (10/54) of MSI (−) tumors (p =0 . 0 5 8 ) .
Methylation of p16 was present in 50% (5/10) of MSI (+)
tumors and in 18.5% (10/54) of MSI (−) tumors (p<0.01).
Relationship between promoter hypermethylation and
expression of hMLH1
Finally, we analyzed the relationship between promoter
hypermethylation of hMLH1 and its expression (Table 4). Of
15 gastric cancers with promoter methylation of hMLH1
gene, 10 (66.7%) showed absent or decreased hMLH1
expression. In contrast, 40 of 49 gastric cancers (81.6%)
without hMLH1 gene methylation showed intense nuclear
immunoreactivity of hMLH1. Absent or decreased hMLH1
expression was significantly correlated with promoter hyper-
methylation of the gene (p<0.001). In addition, hMLH1 pro-
moter hypermethylation was detected in 70% (7/10) of MSI
(+) tumors and was associated with absent or decreased
hMLH1 expression in all 7 cases. In contrast, 8 of 54 (14.8%)
MSI (−) tumors demonstrated hMLH1 promoter hyper-
methylation. Five of these cases showed normal nuclear
immunoreactivity of hMLH1.
Table 2. Comparison of clinicopathological factors between




























Positive 14 8 N.S
N.S.; not significant
Fig. 2.  Representative results of methylation-specific PCR of hMLH1, p16, MGMT and E-cadherin by using both methylated (M) and
unmethylated (U) specific primers in gastric cancer. Methylated PCR products were detected in case 57 for hMLH1, in case 17
and 18 for p16, in case 47, 49 and 50 for MGMT and in case 31 for E-cadherin. P, positive control.Epigenetic Markers for Multiple Early Gastric Cancers
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Discussion
This is the first report to evaluate the MSI status and
hypermethylation of several tumor-related genes in MGCs
of patients treated with EMR. We demonstrated that the
frequency of MSI (+) was significantly higher in the patients
with MGCs than those with SGCs and that hypermethylation
of hMLH1 was more frequently detected in MGCs than in
SGCs (p<0.01). Therefore, MSI (+) and hypermethylation of
hMLH1 may serve as a useful marker for identifying
individuals who may be at risk of developing MGCs.
By the development of the endoscopic therapeutic
techniques, endoscopic resection can cure most of the early
gastric cancers. However, because the background gastric
mucosa in such cases are accompanied by chronic gastritis
and intestinal metaplasia, development of metachronous
multiple gastric cancers in other sites is a major problem.
Uemura et al. [3] reported that no new gastric cancer cases
were detected for 2 years in patients treated with H. pylori
eradication after the resection of the first cancer and on the
other hand, 9% of the patients with H. pylori had meta-
chronous early gastric cancer in other site. Park et al. [21]
reported that the expression of DNA mismatch repair proteins
increased in the gastric mucosa after H. pylori eradication.
Chan et al. [22] showed disappearing of E-cadherin promoter
hypermethylation status after H. pylori eradication in patients
with chronic gastritis. If H. pylori eradication therapy may
reverse methylation of tumor suppressor or tumor-related
genes, early reversal of promoter methylation at the residual
gastric mucosa in the patients treated with EMR may
prevent the development of metachronous gastric cancer.
This indicates the possibility of useful targeting therapy. It is
very valuable to find tumor suppressor or tumor-related
genes that have been methylated in the MGCs of the patients
treated with EMR.
Based on previous reports [9–13], we selected four genes
(hMLH1,  MGMT,  E-cadherin,  p16) and examined the
methylation status of these genes in the present study.
Hypermethylation of hMLH1 was more frequently detected
in MGCs than in SGCs (p<0.01), whereas significant
difference was not observed in the frequency of MGMT, p16
or E-cadherin promoter methylation between the 2 groups.
Regarding hMLH1, it is known that hypermethylation of its
Table 3. Methylation frequencies and number of methylated genes in early multiple gas-
tric cancers and early solitary gastric cancers
Solitary 
gastric cancers
n = 32 (%)
Multiple 
gastric cacners
n = 32 (%)
p value
hMLH1 Unmethylated (%) 27 (84.4) 22 (68.7)
<0.01
Methylated (%) 5 (15.6) 10 (31.3)
MGMTa Unmethylated (%) 19 (59.4) 20 (62.5)
0.653
Methylated (%) 13 (40.6) 12 (37.5)
p16 Unmethylated (%) 25 (78.1) 24 (75.0)
0.605
Methylated (%) 7 (21.9) 8 (25.0)
E-cadherin Unmethylated (%) 25 (78.1) 26 (81.2)
0.586
Methylated (%) 7 (21.9) 6 (18.8)
a MGMT, O6-methylguanine DNA methylyransferase
Fig. 3.  Comparison of the frequency of the promoter hyper-
methylation of hMLH1, MGMT, p16 and E-cadherin in
MSI (+) and MSI (−) gastric cancers. The incidences of
promoter hypermethylation of hMLH1, MGMT and p16
are significantly higher in the MSI (+) tumors than in
the MSI (−) tumors. On the other hand, significant
difference is not observed in the frequency of E-
cadherin promoter methylation between the 2 groups.
Table 4. Correlation with promoter methylation status and pro-
tein expression of hMLH1 in gastric cancers
hMLH1 gene promoter 
Total
hMLH1 immunoreactivity
status Positive (%) Negative (%)
Methylated 15 5 (33.3) 10 (66.7)
a
Unmethylated 49 40 (81.6) 9 (18.4)
a Significant difference (p<0.001) by Fisher’s exact testM. Fukuda et al.
J. Clin. Biochem. Nutr.
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promoter region leads to diminished protein expression and is
significantly associated with genome-wide instability of simple
repeat sequences, referred to as MSI (+) [9, 12, 15, 20]. In
the present study, absent or decreased hMLH1 expression
was significantly correlated with promoter hypermethylation
of the gene by immunohistochemistry. In addition, hMLH1
promoter hypermethylation was detected in 70% of MSI (+)
tumors and was associated with absent or decreased hMLH1
expression in all these cases. In contrast, 14.8% of MSI (−)
tumors demonstrated hMLH1 promoter hypermethylation.
Inactivation of hMLH1 through promoter hypermethylation
may cause MGCs following the MSI pathway.
There were some reports about MSI or hypermethylation
of tumor-related genes in multiple gastric cancers [14–16].
Miyoshi et al. [14] showed that the frequency of MSI was
significantly higher in the patients with multiple gastric
cancers, both synchronous and metachronous, than in those
with a single gastric cancer. Kawamura et al. [ 16] have
reported that thirty percent of patients with metachronous
recurrence of gastric cancer after undergoing successful
endoscopic resection showed MSI, whereas none of the
patients with nonrecurrent disease did so. However, in these
two reports, they did not examine the methylation status of
tumor-related genes in multiple gastric cancers. Sakata et al.
found that hypermethylation of the hMLH1 promoter was
detected in all of SGCs and MGCs with MSI [15]. They
focused on aberrant methylation in a single gene and their
samples were obtained at the time of surgery including only
synchronous multiple gastric cancers. No reports have found
the correlation between the presence of MSI and various
kinds of hypermethylation of tumor-related genes in meta-
chronous multiple gastric cancers.
We also investigated the relationship between the hyper-
methylation of the promoters of four genes (hMLH1,
MGMT, E-cadherin, p16) and MSI. Significant association
was detected between promoter hypermethylation of these
three genes except E-cadherin and MSI (+) cancers (p<0.01).
Some previous reports found that significant associations
were found between hMLH1 promoter hypermethylation and
MSI (+) cancers in different organs [23–25]. In gastric cancer,
Toyota et al. [9] showed that cases showing methylation at
more than three of the five loci (methylated in tumors
(MINT) 1, 2, 12, 25 and 31) were designated as CpG island
methylator phenotype (CIMP) positive, and such CIMP (+)
gastric cancers accompanied with the methylation of known
genes, including p16 and hMLH1. According to these findings,
CpG island methylation may precede the development of
MSI and methylation of some genes may occur in absence of
MSI in many tumors. The results of the present study
indicates that methylation of hMLH1, MGMT, and p16 may
be involved in the development of MSI, and also play a
crucial role in early gastric carcinogenesis. The overall
frequency of E-cadherin promoter hypermethylation in early
gastric carcinomas in the present study was 20.3% (13/64),
which was lower than those previously reported [18, 26, 27].
Tamura et al. [28] showed that E-cadherin promoter hyper-
methylation occurred more frequently in carcinomas of the
undifferentiated scattered type than in other histological sub-
types. The tumors analyzed in this study were histologically
differentiated adenocarcinomas comprising early cancers
(depth of invasion limited to the mucosa or submucosa). This
may affect the frequency of E-cadherin promoter methylation
in this study. If further examination of large sample size is
done, methylation of MGMT and p16, not E-cadherin in
early gastric cancer may be a useful molecular marker for
the prediction of MGC development.
In conclusion, hMLH1 may be one of the frequent methy-
lation targets in MGCs and its inactivation through promoter
hypermethylation may cause MGCs following the MSI
pathway. MSI (+) and hMLH1 methylation in gastric cancer
may be a useful molecular marker for the prediction of MGC
development and these patients will need to be closely
observed by endoscopy as high risk patients even if the treat-
ment with EMR were successful. We also put our hopes in
developing some gene-targeting therapies that may reverse
methylation at the residual gastric mucosa in the patients
treated with EMR in order to prevent the development of
metachronous gastric cancer.
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